Accuray Incorporated (ARAY) : Traders are negative on Accuray Incorporated (ARAY), as it has 12.4% of short positions outstanding compared to its float. The total shorts have reduced by -1,303,168 shares, which is a -12% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,10,900,744 to 9,597,576 shares. While the daily trading volume of the stock is 386,701, there are 25 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Accuray Incorporated (NASDAQ:ARAY): The stock opened at $5.30 on Wednesday but the bulls could not build on the opening and the stock topped out at $5.32 for the day. The stock traded down to $5.20 during the day, due to lack of any buying support eventually closed down at $5.24 with a loss of -1.87% for the day. The stock had closed at $5.34 on the previous day. The total traded volume was 515,036 shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Accuray Inc, Levine Joshua had purchased shares worth of $356,000 in a transaction dated on November 9, 2015. A total of 50,000 shares were purchased at a price of $7.12 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.